Patient Support Line 1-866-433-8000, Monday - Friday: 8:00 AM to 8:00 PM ET

More Reasons to Believe
Even years after an initial diagnosis of HR+, HER2- Stage 2 or 3 early breast cancer (eBC) with a high risk of coming back, cancer can return, including in other areas of the body. When cancer spreads to other areas of the body, it is called metastatic breast cancer (mBC). That's why choosing the right treatment now is so important. KISQALI is taken with a specific kind of hormone therapy called an aromatase inhibitor (AI).
*For people who have stage 2 or stage 3 hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) eBC with a high risk of coming back, including people with and without cancer in their lymph nodes, and people who are pre- or postmenopausal.
Results from the clinical trial were reviewed at 3 and 4 years. The benefit of KISQALI was shown to increase over time.
When the results were reviewed at 3 years
| When the results were reviewed at 4 years†
|
†Results from the 4-year analysis were not designed to detect a false positive or show a difference between treatments.
Leading cancer experts choose ribociclib (KISQALI®)
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), written by leading cancer experts, recommend ribociclib (KISQALI®) + an AI as an option for eligible patients with HR+, HER2- early breast cancer—to help prevent cancer from coming back.
KISQALI is approved for people with HR+, HER2- stage 2 or 3 early breast cancer with a high risk of coming back.
KISQALI + an AI was studied and proven to reduce the risk of cancer coming back in:
- People who were premenopausal or postmenopausal
- People who had stage 2 or stage 3 eBC with a high risk of coming back
- People with and without cancer in their lymph nodes

Results with KISQALI glossary
Learn more about key terms used on this page by tapping or clicking the words below.